Xuanzhu Biopharmaceutical climbs to three-week high on approval for drug clinical trial

Xuanzhu Biopharmaceutical

15/04/2026 03:21

** Shares of Xuanzhu Biopharmaceutical 2575.HK jump as much as 25.8% to HK$41, their highest level since March 26

** Stock marks its biggest one-day pct rise since October 22

** Xuanzhu says China's National Medical Products Administration has approved the company to initiate a Phase III clinical trial of bismuth-containing quadruple therapy comprising Anaprazole Sodium Enteric-coated tablets for the eradication of Helicobacter pylori

** The market size of drugs for treatment of Helicobacter pylori, which closely associated with gastric diseases including gastric ulcer, chronic progressive gastritis and gastric cancer, reached 5.5 billion yuan ($806.81 million) in 2024, and is projected to reach 6.8 billion yuan in 2029 and to 12.6 billion yuan in 2035, says Xuanzhu

** The approval of the Phase III clinical trial application for the new indication of Anaprazole Sodium helps to enhance the company's influence in the field of digestive disease treatment, Xuanzhu says

** YTD, stock down 47.8%, while Hang Seng Biotech Index .HSBIO up 9.8%

   ($1 = 6.8170 Chinese yuan)

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))